Novel hypoglycemic injury mechanism: N-methyl-D-aspartate receptor-mediated white matter damage

Ann Neurol. 2014 Apr;75(4):492-507. doi: 10.1002/ana.24050. Epub 2014 Mar 26.

Abstract

Objective: Hypoglycemia is a common adverse event and can injure central nervous system (CNS) white matter (WM). We determined whether glutamate receptors were involved in hypoglycemic WM injury.

Methods: Mouse optic nerves (MON), CNS WM tracts, were maintained at 37°C with oxygenated artificial cerebrospinal fluid (ACSF) containing 10mM glucose. Aglycemia was produced by switching to 0 glucose ACSF. Supramaximal compound action potentials (CAPs) were elicited using suction electrodes, and axon function was quantified as the area under the CAP. Amino acid release was measured using high-performance liquid chromatography. Extracellular lactate concentration ([lactate(-)]o) was measured using an enzyme electrode.

Results: About 50% of MON axons were injured after 60 minutes of aglycemia (90% after 90 minutes); injury extent was not affected by animal age. Blockade of N-methyl-D-aspartate (NMDA)-type glutamate receptors improved recovery after 90 minutes of aglycemia by 250%. Aglycemic injury was increased by reducing [Mg(2+)]o or increasing [glycine]o , and decreased by lowering pHo , expected results for NMDA receptor-mediated injury. pHo increased during aglycemia due to a drop in [lactate(-)]o. Aglycemic injury was dramatically reduced in the absence of [Ca(2+)]o. Extracellular aspartate, a selective NMDA receptor agonist, increased during aglycemia ([glutamate]o fell).

Interpretation: Aglycemia injured WM by a unique excitotoxic mechanism involving NMDA receptors (located primarily on oligodendrocytes). During WM aglycemia, the selective NMDA agonist aspartate is released, probably from astrocytes. Injury is mediated by Ca(2+) influx through aspartate-activated NMDA receptors made permeable by an accompanying alkaline shift in pHo caused by a fall in [lactate(-)]o. These insights have important clinical implications.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Aspartic Acid / metabolism
  • Brain / drug effects
  • Calcium / metabolism
  • Disease Models, Animal
  • Excitatory Amino Acid Agonists / pharmacology
  • Excitatory Amino Acid Antagonists / therapeutic use
  • Glutamic Acid / metabolism
  • Glycine / metabolism
  • Glycogen / metabolism
  • Hydrogen-Ion Concentration
  • Hypoglycemia / complications
  • Kynurenic Acid / analogs & derivatives
  • Kynurenic Acid / therapeutic use
  • Lactic Acid / metabolism
  • Leukoencephalopathies / drug therapy
  • Leukoencephalopathies / etiology*
  • Leukoencephalopathies / metabolism
  • Mice
  • Mice, Inbred C57BL
  • Optic Nerve Injuries / drug therapy
  • Optic Nerve Injuries / etiology*
  • Optic Nerve Injuries / metabolism*
  • Quinoxalines / therapeutic use
  • Receptors, N-Methyl-D-Aspartate / metabolism*
  • alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid / pharmacology

Substances

  • Excitatory Amino Acid Agonists
  • Excitatory Amino Acid Antagonists
  • Quinoxalines
  • Receptors, N-Methyl-D-Aspartate
  • 2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline
  • Aspartic Acid
  • Lactic Acid
  • Glutamic Acid
  • alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid
  • Glycogen
  • Kynurenic Acid
  • 7-chlorokynurenic acid
  • Calcium
  • Glycine